{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2014-06-19T18%3A57%3A29.690Z&min-dateTabled=2014-06-04&answeringDeptId=17&max-questionFirstAnswered.=2014-06-11T11%3A45%3A03.2927005Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpCreated=2014-06-19T18%3A57%3A29.690Z&min-dateTabled=2014-06-04&answeringDeptId=17&max-questionFirstAnswered.=2014-06-11T11%3A45%3A03.2927005Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2014-06-19T18%3A57%3A29.690Z&min-dateTabled=2014-06-04&answeringDeptId=17&_metadata=all&max-questionFirstAnswered.=2014-06-11T11%3A45%3A03.2927005Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpCreated=2014-06-19T18%3A57%3A29.690Z&min-dateTabled=2014-06-04&answeringDeptId=17&max-questionFirstAnswered.=2014-06-11T11%3A45%3A03.2927005Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2014-06-19T18%3A57%3A29.690Z&min-dateTabled=2014-06-04&answeringDeptId=17&max-questionFirstAnswered.=2014-06-11T11%3A45%3A03.2927005Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2014-06-19T18%3A57%3A29.690Z&min-dateTabled=2014-06-04&answeringDeptId=17&max-questionFirstAnswered.=2014-06-11T11%3A45%3A03.2927005Z", "items" : [{"_about" : "http://data.parliament.uk/resources/58392", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58392/answer", "answerText" : {"_value" : "<p>The Government has noted the report and is currently considering how to respond to the recommendations<strong>.<\/strong><\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:23:48.5303857Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Sunbeds"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, whether the Government plans to respond to the recommendations set out in the report of the All Party Parliamentary Group on Skin on sunbed regulation published in 2014.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
      ], "uin" : "199381"}
    , {"_about" : "http://data.parliament.uk/resources/58393", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58393/answer", "answerText" : {"_value" : "<p>We have not made any estimate of extending the human papillomavirus (HPV) vaccination programme to include boys aged 12 and 13 years, as the Joint Committee on Vaccination and Immunisation has not yet completed its consideration of whether HPV vaccine should be offered to males.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T14:44:56.5091119Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the potential cost of extending the human papilloma virus vaccination programme to include all boys aged 12 and 13 years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
      ], "uin" : "199382"}
    , {"_about" : "http://data.parliament.uk/resources/58394", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58394/answer", "answerText" : {"_value" : "<p>Research in the evidence around the effectiveness of alcohol harm reduction communications and related campaigns suggests that labelling and point of sale information can have an impact on consumption, in conjunction with broader campaigns to raise consumer awareness and education on the health risks linked to alcohol consumption.<\/p><p><strong> <\/strong><\/p><p>As part of the Public Health Responsibility Deal, alcohol retailers and producers have committed to putting an agreed warning or a pregnancy warning logo on 80% of labels on bottles and cans by the end of 2013. An independent market survey is underway to measure compliance. This level of coverage should allow the majority of consumers to see the pregnancy warning and logo.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:29:37.6664142Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Pregnancy: Alcoholic Drinks"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what the Government's assessment is of the effectiveness of warning labels on alcoholic beverages regarding drinking during pregnancy; and what assessment he has made of the potential benefits of making such labels mandatory.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
      ], "uin" : "199389"}
    , {"_about" : "http://data.parliament.uk/resources/58395", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58395/answer", "answerText" : {"_value" : "<p>The information requested is not available.<\/p><p> <\/p><p>NHS England advises us that individual funding levels and programme costs vary between Academic Health Science Networks (AHSNs). NHS England budget allocations are not their sole source of income and AHSNs are seeking to supplement this funding through participation in strategic investment programmes and match-funding initiatives. Core running costs are for AHSNs to determine independently and may also be subject to change through the year.<\/p><p> <\/p><p>Further information on AHSN work programmes and business plans can be found on their websites:<\/p><p> <\/p><table><tbody><tr><td><p>AHSN<\/p><\/td><td><p>Website<\/p><\/td><\/tr><tr><td><p>East Midlands<\/p><\/td><td><p><a href=\"http://www.emahsn.ac.uk/\" target=\"_blank\">www.emahsn.ac.uk<\/a><\/p><\/td><\/tr><tr><td><p>Eastern<\/p><\/td><td><p><a href=\"http://www.eahsn.org.uk/\" target=\"_blank\">www.eahsn.org.uk<\/a><\/p><\/td><\/tr><tr><td><p>Imperial College Health Partners<\/p><\/td><td><p><a href=\"http://www.imperialcollegehealthpartners.com/\" target=\"_blank\">www.imperialcollegehealthpartners.com<\/a><\/p><\/td><\/tr><tr><td><p>Greater Manchester<\/p><\/td><td><p><a href=\"http://www.gmahsn.org/\" target=\"_blank\">www.gmahsn.org<\/a><\/p><\/td><\/tr><tr><td><p>Kent, Surrey and Sussex<\/p><\/td><td><p><a href=\"http://www.kssahsn.net/\" target=\"_blank\">www.kssahsn.net<\/a><\/p><\/td><\/tr><tr><td><p>North East and North Cumbria<\/p><\/td><td><p><a href=\"http://www.ahsn-nenc.org.uk/\" target=\"_blank\">www.ahsn-nenc.org.uk<\/a><\/p><\/td><\/tr><tr><td><p>North West Coast<\/p><\/td><td><p><a href=\"http://www.nwcahsn.nhs.uk/\" target=\"_blank\">www.nwcahsn.nhs.uk<\/a><\/p><\/td><\/tr><tr><td><p>Oxford<\/p><\/td><td><p><a href=\"http://www.oxfordahsn.org/\" target=\"_blank\">www.oxfordahsn.org<\/a><\/p><\/td><\/tr><tr><td><p>South London<\/p><\/td><td><p><a href=\"http://www.kingshealthpartners.org/info/southlondonahsn\" target=\"_blank\">www.kingshealthpartners.org/info/southlondonahsn<\/a><\/p><\/td><\/tr><tr><td><p>South West Peninsula<\/p><\/td><td><p><a href=\"http://www.swahsn.com/\" target=\"_blank\">www.swahsn.com<\/a><\/p><\/td><\/tr><tr><td><p>UCL Partners<\/p><\/td><td><p><a href=\"http://www.uclpartners.com/\" target=\"_blank\">www.uclpartners.com<\/a><\/p><\/td><\/tr><tr><td><p>Wessex<\/p><\/td><td><p><a href=\"http://www.wessexahsn.org/\" target=\"_blank\">www.wessexahsn.org<\/a><\/p><\/td><\/tr><tr><td><p>West Midlands<\/p><\/td><td><p><a href=\"http://www.wmahsn.org/\" target=\"_blank\">www.wmahsn.org<\/a><\/p><\/td><\/tr><tr><td><p>West of England<\/p><\/td><td><p><a href=\"http://www.weahsn.net/\" target=\"_blank\">www.weahsn.net<\/a><\/p><\/td><\/tr><tr><td><p>Yorkshire and Humber<\/p><\/td><td><p><a href=\"http://www.yhahsn.org.uk/\" target=\"_blank\">www.yhahsn.org.uk<\/a><\/p><\/td><\/tr><\/tbody><\/table><p> <\/p><p> <\/p><p> <\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
        }
        , "answeringMemberConstituency" : {"_value" : "North Norfolk"}
        , "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T14:27:05.6934122Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Academic Health Science Networks"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what the running costs for each of the academic health science networks are.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
      }
      , "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
      , "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
      ], "uin" : "199345"}
    , {"_about" : "http://data.parliament.uk/resources/58513", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58513/answer", "answerText" : {"_value" : "<p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.<\/p><p> <\/p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.<\/p><p> <\/p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.<\/p><p> <\/p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.<\/p><p> <\/p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.<\/p><p> <\/p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.<\/p><p> <\/p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "199303"}
        , {"_value" : "199304"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:28:08.1244279Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prostate Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4022", "label" : {"_value" : "Biography information for Oliver Colvile"}
      }
      , "tablingMemberConstituency" : {"_value" : "Plymouth, Sutton and Devonport"}
      , "tablingMemberPrinted" : [{"_value" : "Oliver Colvile"}
      ], "uin" : "199302"}
    , {"_about" : "http://data.parliament.uk/resources/58515", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58515/answer", "answerText" : {"_value" : "<p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.<\/p><p> <\/p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.<\/p><p> <\/p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.<\/p><p> <\/p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.<\/p><p> <\/p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.<\/p><p> <\/p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.<\/p><p> <\/p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "199302"}
        , {"_value" : "199304"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:28:10.7493701Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prostate Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4022", "label" : {"_value" : "Biography information for Oliver Colvile"}
      }
      , "tablingMemberConstituency" : {"_value" : "Plymouth, Sutton and Devonport"}
      , "tablingMemberPrinted" : [{"_value" : "Oliver Colvile"}
      ], "uin" : "199303"}
    , {"_about" : "http://data.parliament.uk/resources/58516", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/58516/answer", "answerText" : {"_value" : "<p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.<\/p><p> <\/p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.<\/p><p> <\/p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.<\/p><p> <\/p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.<\/p><p> <\/p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.<\/p><p> <\/p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.<\/p><p> <\/p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
        }
        , "answeringMemberConstituency" : {"_value" : "Battersea"}
        , "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "199302"}
        , {"_value" : "199303"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:28:11.1243643Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Prostate Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4022", "label" : {"_value" : "Biography information for Oliver Colvile"}
      }
      , "tablingMemberConstituency" : {"_value" : "Plymouth, Sutton and Devonport"}
      , "tablingMemberPrinted" : [{"_value" : "Oliver Colvile"}
      ], "uin" : "199304"}
    , {"_about" : "http://data.parliament.uk/resources/57541", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/57541/answer", "answerText" : {"_value" : "<p>General practitioners (GPs) must ensure that patients have provided explicit consent before disclosing information to insurance companies. Additionally, under the provisions of the Access to Medical Reports Act 1988, patients have the right to view medical reports prepared for insurance companies and, where a patient has exercised this right, a GP cannot disclose the report to the insurance company until the patient has had the opportunity to review it or if the patient withdraws their consent.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-06-11", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-11T11:45:03.2927005Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Records: Data Protection"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what are the rules relating to the release of patients' private medical information to insurance companies by general practitioners.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1813", "label" : {"_value" : "Biography information for Lord Trefgarne"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Trefgarne"}
      ], "uin" : "HL14"}
    , {"_about" : "http://data.parliament.uk/resources/57554", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/57554/answer", "answerText" : {"_value" : "<p>The appointment of Trust Special Administrators (TSAs) to Mid-Staffordshire NHS Foundation Trust in April 2013 was made by Monitor. The TSAs' final proposals were accepted by Monitor in January 2014, and by the Secretary of State in February 2014.<\/p><p> <\/p><p>In an announcement on 13 March 2014, Monitor stated that the costs of the process to date had been £7,250,000, with an additional £250,000 incurred by the team of administrators in expenses.<\/p><p><strong> <\/strong><\/p><p>Following the Secretary of State's acceptance of the proposals, the TSAs have remained in post to continue with the day to day management of the Trust and to work on implementing the proposals.<\/p><p><strong> <\/strong><\/p><p>In the announcement Monitor anticipated that the overall cost of the TSA contract for the lifetime of the project would be between £12 million and £15 million.<\/p><p><strong> <\/strong><\/p><p>Monitor's announcement can be found on its website at:<\/p><p> <\/p><p>www.gov.uk/government/news/mid-staffs-monitor-announces-next-steps<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/2000", "label" : {"_value" : "Biography information for Earl Howe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Earl Howe"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:28:17.591657Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mid Staffordshire NHS Foundation Trust"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what is their estimate of the cost of the special administration process in relation to Mid-Staffordshire NHS Trust.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/2024", "label" : {"_value" : "Biography information for Lord Hunt of Kings Heath"}
      }
      , "tablingMemberPrinted" : [{"_value" : "Lord Hunt of Kings Heath"}
      ], "uin" : "HL27"}
    , {"_about" : "http://data.parliament.uk/resources/57602", "AnsweringBody" : [{"_value" : "Department of Health"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/57602/answer", "answerText" : {"_value" : "<p>The Medicines and Healthcare products Regulatory Agency (MHRA) expect everyone involved in a clinical trial to be qualified and trained to perform their tasks (as per Schedule 1, part 2 (2) of the Medicines for Human Use (Clinical Trials) Regulations(SI 2004/1031).<\/p><p> <\/p><p>Staff of pharmaceutical companies are not \u201cconducting\u201d a trial as defined in the clinical trial regulation (SI 2004/1031 Reg 2 \u201cinterpretation\u201d). However, the same Good Clinical Practice principles apply to those involved in clinical trial activities; i.e. they should be qualified and trained to perform their tasks. At sponsor site inspection, inspectors will verify the training records, CV, and job description of selected employees to confirm adequate training has been given.<\/p><p> <\/p><p>Sponsors are expected to carry out checks in audits or monitoring to ensure that on completion of training, staff are indeed carrying out their duties according to requirements and/or procedures (these checks should be documented in monitoring/audit reports). Inspectors check the monitoring visit reports to determine non-compliances are adequately followed up and re-training is given to site personnel when necessary.<\/p><p> <\/p><p>The voluntary MHRA Phase 1 Accreditation Scheme requires that a Principal Investigator (PI) for a First in Human study has relevant experience and a post graduate qualification in pharmaceutical medicine (such as a Diploma in Pharmaceutical medicine, Diploma in Human Pharmacology, MSc in Clinical Pharmacology or equivalent). An exemption to this requirement has been issued for PI's that do not have a post graduate qualification but are able to demonstrate that they have a significant amount of experience in this field (and are often involved in teaching the post-graduate courses). An application for an exemption is assessed independently by the Faculty of Medicine.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
        }
        , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
        , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
        , "dateOfAnswer" : {"_value" : "2014-06-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2014-06-10T15:11:34.4598073Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health"}
      , "answeringDeptSortName" : {"_value" : "Health"}
      , "date" : {"_value" : "2014-06-04", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Clinical Trials"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health, what steps are taken to verify the competence of (a) doctors and nurses and (b) staff of pharmaceutical companies involved in the conduct of clinical trials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1506", "label" : {"_value" : "Biography information for Andrew Gwynne"}
      }
      , "tablingMemberConstituency" : {"_value" : "Denton and Reddish"}
      , "tablingMemberPrinted" : [{"_value" : "Andrew Gwynne"}
      ], "uin" : "198571"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-ddpCreated=2014-06-19T18%3A57%3A29.690Z&min-dateTabled=2014-06-04&answeringDeptId=17&max-questionFirstAnswered.=2014-06-11T11%3A45%3A03.2927005Z", "page" : 0, "startIndex" : 1, "totalResults" : 70, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}